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tion with a 95:2.5:2.5 ratio of TFA to H 2 O to triisopropylsilane (TIPS). Peptides were cleaved from the resin by a 30-45 min incubation with a 100 mM sodium hydroxide solution. The resulting basic solution was neutralized with 100 mM phosphate buffer, pH 6.5. The cleaved peptides were purified using reverse-phase HPLC with a gradient of water/CH 3 CN with 0.1% TFA. The organic solvent was removed on a vacuum centrifuge and the remaining water was removed by lyophilization. The lyophilized peptides were dissolved in 10 mM phosphate buffer, pH 7.5 and the concentration was adjusted to 1 mM based on absorbance.
S.4 Peptide modification
General methods. The small molecule coupling partners (2-amino-p-cresol and 4-methylcatechol) were purchased from Sigma Aldrich and purified by sublimation. 2 The purified small molecules were stored frozen (at -80 °C) as a 500 mM solution in CH 3 CN and diluted to 1 mM before use. Potassium ferricyanide (99.99% trace metal basis) was purchased from Sigma Aldrich and used without further purification. Commercial peptides were dissolved in ddH 2 O to an approximate concentration of 1 mM. The dissolved peptides were stored between 4 °C and -20 °C to prevent degradation. When using high ionic strength buffers, peptide solutions were purified using Millipore ZipTip C18 Pipette Tips as specified by the supplier before analysis by MALDI-TOF MS.
General method for the modification of commercial peptides. To a solution of peptide (1 nmol, final concentration 100 μM) in buffer was added 2-amino-p-cresol or 4-methylcatechol (1-5 nmol, from a 1 mM stock containing 0.2% CH 3 CN, final concentration 100-500 μM). To these reagents was added 1 μL of a solution of K 3 Fe(CN) 6 (10 or 50 mM stock solution, final concentration 1-5 mM) to start the reaction. The reaction was immediately vortexed and allowed to incubate at room temperature for the indicated time. The peptides were either purified or co-crystallized with matrix on the MALDI plate at the indicated time to stop the reaction. The percent modification was determined using MALDI-TOF MS. Given the high variability in signal in MALDI-TOF MS these values were used only for comparison.
Angiotensin modification for MS/MS analysis.
To a solution of angiotensin (10 nmol, final concentration 100 μM) in 50 mM phosphate buffer, pH 7.5 was added 2-amino-p-cresol (10 nmol, final concentration 100 μM). K 3 Fe(CN) 6 was added (10 μL of a 10 mM solution, final concentration 1 mM) to start the reaction. After 30 min, the reaction was purified on a C18 Sep-Pak (Waters, conditioned with CH 3 OH, equilibrated and washed with H 2 O with 0.1% TFA, and eluted with CH 3 CN). The solvent was removed under reduced pressure and the peptide was redissolved in ddH 2 O for analysis.
General method for the modification of synthetic peptides. To a solution of peptide (2 nmol, final concentration 100 μM) in buffer was added 2 equiv of 2-amino-p-cresol (4 nmol, final concentration 200 μM) followed by addition of 100 nmol of K 3 Fe(CN) 6 . The solution was immediately mixed after addition of the oxidant. Reactions were incubated at room temperature for the indicated time. The reactions were quenched by addition of buffered tris(2-carboxyethyl)phosphine hydrochloride (0.5 M solution of TCEP pH 7.0, 1 μmol) and analyzed by LC-MS.
Method for the sequential modification of PAD(pAF)SWAG. To a solution of peptide (20 nmol, final concentration 100 μM) in phosphate buffer, pH 6.0 was added 2-amino-p-cresol (40 nmol, final concentration 200 μM) followed by K 3 Fe(CN) 6 (1 μmol, 5 mM final concentration). The reaction was vortexed immediately following addition of the oxidant. After 30 min of incubation at room temperature the reaction was purified on a C18 Sep-Pak (conditioned with CH 3 OH, equilibrated and washed with H 2 O with 0.1% TFA, and eluted with CH 3 CN). The solvent was removed under reduced pressure and the peptide was redissolved in 10 mM phosphate buffer, pH 7.5. The purified peptide was modified for a second time following the general method described above.
S.5
Small molecule synthesis.
Synthesis of proline product (S1). To 150 mL of buffered ddH 2 O (10 mM phosphate buffer, pH 7.5) was added 4-methylcatechol (24.2 mg, 0.2 mmol, purified by sublimation and recrystallization from toluene) in 400 μL of MeCN and L-proline methyl ester hydrochloride (33.1 mg, 0.2 mmol) in 1 mL 100 mM phosphate buffer pH 9.0. To the rapidly stirred solution was added potassium ferricyanide (690 mg, 2.1 mmol, as a solution in 50 mL of buffer). After stirring at rt for 20 min, the reaction mixture was extracted with 3 portions of 100 mL 30% 2-propanol in CHCl 3 . The combined organic layers were dried over sodium sulfate and the solvent was removed in vacuo. The resulting deep purple solid was taken up in CDCl 3 for characterization 1 30.62, 53.11, 53.60, 63.81, 103.45, 132.12, 146.41, 157.62, 171.53, 176.37, 182.16. HRMS (ESI) 48, 171.74, 155.24, 146.88, 136.88, 130.73, 130.10, 129.81, 128.95, 98.07, 57.67, 53.43, 37.34, 18.17 
Synthesis of 3-(4-hydroxy-3-nitrophenyl) propionic acid (S3).
The nitrophenol was synthesized as previously reported.
3 Briefly, to a solution of 3-(4-hydroxyphenyl)propionic acid (5 g, 30.1 mmol) in 25 mL acetic acid at 15 °C was added a solution of fuming nitric acid (1.6 mL, 33.8 mmol) in acetic acid (4 mL). The solution immediately turned orange. After 15 min the reaction was quenched by addition to ice water. The precipitate was filtered and dried. The yellow precipitate was recrystallized from 1:1 ethanol:water to afford 3.07 g of a yellow powder (48% yield). 
13
C NMR (100 MHz, CDCl 3 ): δ 178. 22, 153.86, 138.11, 133.47, 132.60, 124.22, 120.27, 35.19, 29.37 
Synthesis of 3-(4-hydroxy-3-nitrophenyl) propionic acid NHS ester (S4).
The nitrophenol NHS ester was synthesized as previously reported. 3 To a solution of S3 (1 g, 4.7 mmol) and N-hydroxysuccinimide (0.65 g, 5.7 mmol) in CH 2 Cl 2 at 0 °C was added N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (1.09 g, 5.7 mmol). The reaction was stirred for 2 h and then diluted with DCM and washed with water. The combined organic layers were dried over sodium sulfate and the solvent was removed in vacuo. The reaction afforded 1.38 g of a yellow solid (94% yield). 167.56, 154.09, 138.00, 133.54, 131.40, 124.52, 120.49, 32.48, 29.43, 25.70 
S.6 UV-Vis kinetics
Pseudo-first order reactions. To 50 mM phosphate buffer (either pH 6.0 or 7.5) was added 10 μL of a 10 mM solution of 4-methylcatechol (final concentration 100 μM) and 100 μL of a 10 mM solution of the coupling partner (p-toluidine, H-ProOMe, or H-Phe-OMe, final concentration 1 mM) for a volume of 900 μL. This solution was used as a blank before measurement. The absorbance at 520 nm was monitored every 1 s for 3600 s using a Cary 50 spectrophotometer. Within the first 1 s of measurement, 100 μL of a 100 mM solution of K 3 Fe(CN) 6 (final concentration 10 mM) was added for a final reaction volume of 1 mL. A control reaction was run that excluded the amine coupling partner to verify the increase in absorbance at 520 nm did not arise from simple oxidation of the catechol substrate. The data were normalized to account for differences in extinction coefficients of the products. The raw data are shown in Supporting Information Figure S12 . Second order reactions. To 50 mM phosphate buffer pH 7.5 was added 10 μL of a 10 mM solution of 4-methylcatechol (final concentration 100 μM) and 10 μL of a 10 mM solution of H-Pro-OMe (final concentration 100 μM) for a final volume of 900 μL. This solution was used as a blank before measurement. The absorbance at 520 nm was monitored every 0.1 s for 3600 s at 25 °C using a Cary 50 spectrophotometer outfitted with a temperature control unit. Within the first 5 s of measurement, 100 μL of a 100 mM solution of K 3 Fe(CN) 6 (final concentration 10 mM) was added. The reactions were performed in triplicate. A calibration curve was constructed by measuring the absorbance of reactions set up under pseudo-first order conditions with 10, 25, 50, 100, 250, 500 and 1000 μM catechol. The second order rate constants were calculated using the Cary software.
S.7 Aminophenol substrate synthesis
Synthesis of o-aminophenol rhodamine. The fluorescent aminophenol was synthesized as previously reported. 3 To a solution of Rhodamine B piperazine amide 4 (50 mg, 0.1 mmol) in DMF (1 mL) was added diisopropylethylamine (35 μL, 0.2 mmol) followed by S4 (30 mg, 0.1 mmol). After stirring for 2 h the solvent was removed in vacuo. The product was purified on silica gel with a gradient of CH 2 Cl 704.3433, found 704.3436 m/z. To a 1 mg portion of the nitrophenol rhodamine in 100 μL of 100 mM phosphate buffer, pH 6.5 was added an equal volume of a freshly prepared 100 mM solution of sodium dithionite in 100 mM phosphate buffer, pH 6.5. After 20 min, the excess dithionite was removed by purification on a C18 Sep-Pak according to the manufacturer's instructions. The eluent was concentrated to dryness. The rhodamine aminophenol was resuspended in DMF and stored frozen as a 50 mM solution.
Synthesis of o-aminophenol 5k-PEG.
The o-aminophenol PEG substrate was synthesized following a previously published protocol.
3 Briefly, to a solution of mPEG-NH 2 (MW=5000, 115 mg, 0.023 mmol) in CH 2 Cl 2 (1 mL) was added triethylamine (7 μL, 0.05 mmol) and S4 (99 mg, 0.32 mmol as a 0.4 M solution in DMSO). The solution was stirred for 2 h at rt and then the solvent was removed in vacuo. Excess S4 was precipitated by the addition of water. The resulting solution was filtered through a 0.22 micron filter and three Sephadex size exclusion columns (one NAP-10 and two NAP-25, GE Healthcare) according to the manufacturer's instructions. The modified PEG was further purified by precipitation from CH 2 Cl 2 with Et 2 O three times. Reduction of the nitrophenol was accomplished with sodium dithionite. To a 1 mM solution of the modified PEG was added an equal volume of a freshly prepared 120 mM solution of sodium dithionite in 100 mM phosphate buffer, pH 6.5. Excess dithionite was removed by purification with three Sephadex size exclusion columns. The purified aminophenol PEG was lyophilized and resuspended in 10 mM phosphate buffer, pH 7.2. The concentration was adjusted to 1 mM by measuring the aminophenol absorbance at 290 nm. The final solution of o-aminophenol PEG was stored in single use aliquots at -20 °C until use.
S.8 Protein expression and purification
The QuikChange II Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used to introduce N-terminal proline mutations to GFP and TMV.
The N-terminus of a previously generated GFP mutant was changed from alanine to proline using the primers :
The N-terminus of TMV mutants was extended from the native N-terminus of SYS to PAGSYS using the primers :
The TMV coat protein already had the following mutations : K53R, K68R (RR-TMV) and either S123C or T104K. an equal volume of 100% (NH 4 ) 2 SO 4 and rotated at 4 °C for 10 min to precipitate the protein. The precipitated protein was collected by centrifugation at 16000 g for 45 min and then resuspended in 10 mL lysis buffer. The resuspended protein was applied to a DEAE-Sephadex column and purified using the following gradient (buffer A: 20 mM TEA, pH 7.2, buffer B: 20 mM TEA, pH 7.2 with 1 M NaCl): 0 min (0% B), 60 min (30% B), 61 min (100% B), 90 min (100% B), 91 min (0% B), 120 min (0 %B) with a flow rate of 3 mL/min. The fractions containing pure TMV were combined and then buffer exchanged into 10 mM phosphate buffer, pH 7.5 using spin concentrators with a 100 kDa MWCO.
Expression and purification of wt-GFP and Pro-GFP. The plasmids were transformed into T7 Express lysY/I q cells for expression. The cells were grown in 1 L of LB with 100 μg/L of ampicillin at 37 °C until induction, at which point the temperature was lowered to 16-25 °C. The cells were induced by addition of 1 mL of 0.3 M IPTG. The cells were collected by centrifugation at 8000 rpm for 15 min and then resuspended in 10-15 mL lysis buffer (20 mM Tris, 150 mM NaCl, 5 mM EDTA, pH 8.0). The cells were lysed by sonication. The lysate was clarified by centrifugation at 9000 rpm for 1 h. The lysate was applied to 5-7 mL of chitin resin pre-rinsed with 100 mL of lysis buffer. The resin was rinsed with 100 mL wash buffer (20 mM Tris, 500 mM NaCl 1 mM EDTA, pH 8.0) and then incubated with 20 mL cleavage buffer (wash buffer with 50 mM sodium 2-mercaptoethanesulfonate (MESNa)) for 48 h. The cleaved protein was eluted with an additional 20 mL wash buffer and then buffer exchanged into 10 mM phosphate buffer, pH 7.5 using spin concentrators with a 10 kDa molecular weight cutoff (MWCO).
S.9 Protein Modification
Disulfide exchange with Ellman's reagent. Free cysteines were protected from potential modification by disulfide formation with Ellman's reagent (5,5'-dithiobis-(2-nitrobenzoic acid), DTNB). To a solution of PAG RR-TMV S123C (780 μL of a 100 μM solution) was added DTNB (20 μL of a 20 mM solution in 100 mM phosphate buffer, pH 7.2 with 1 mM EDTA). The reaction mixture was incubated at rt for 15 min and then the excess DTNB was removed by repeated (3-6 times) centrifugal filtration against a 100 kDa MWCO membrane. To reduce the disulfide, approximately 25 equiv of TCEP (as a 0.5 M solution, pH 7.0) was added to the protein sample.
General procedure for oxidative coupling on proteins. To a solution of proline terminal protein (PAG RR-TMV, Pro-GFP, creatine kinase, 5-20 μM) in 10 mM phosphate buffer, pH 7.5 was added 2-10 equiv of the o-aminophenol coupling partner (20-100 μM). The solution was briefly vortexed and then 10-20 equiv (relative to the o-aminophenol) of K 3 Fe(CN) 6 (as a 50 mM solution in 10 mM phosphate buffer, pH 7.5) was added. After 20-30 min, the reaction was purified using a Sephadex size exclusion column (GE Healthcare) according to the manufacturer's instructions or using a 0.5 mL centrifugal filter with an appropriate molecular weight cut off (MWCO, Millipore). Modification was monitored by SDS-PAGE or LC-MS.
Oxidative coupling and tryptic digestion. To a solution of proline-GFP (20 μM) in 10 mM phosphate buffer, pH 7.5 was added 5 equiv of 2-amino-p-cresol (100 μM). The solution was briefly vortexed and then 10 equiv of K 3 Fe(CN) 6 (1 mM as a solution in 10 mM phosphate buffer, pH 7.5) was added. After 30 min, the reaction was purified using a 0.5 mL centrifugal filter with a 10 kDa MWCO. For the tryptic digest, a modified procedure from Strader et. al. was followed. 5 To a 40 μL solution of the modified protein (20 μg) in 50 mM Tris buffer, pH 7.6 was added 160 μL MeCN and 2 μL of a 100 mM solution of CaCl 2 . To the denatured protein solution was added 400 ng trypsin. After incubation at 37 °C for 1 h, 8.4 μL of a freshly made 500 mM DTT solution was added. The resulting solution was incubated at 37 °C for 1 h. The reaction solvent was removed from the digested protein sample by vacuum centrifugation. After reaching dryness, the resulting solid was resuspended in ddH 2 O and lyophilized. The digested protein was resuspended in ddH 2 O and analyzed by LC-MS/MS.
Cysteine alkylation with fluorescent maleimides.
A solution of PAG RR-TMV S123C (100 μM) in 10 mM phosphate buffer, pH 8.0 was incubated with 1 equivalent of an Alexa Fluor maleimide (Alexa Fluor 488 C 5 -maleimide, 20 mM in DMSO) for 2 h. Unreacted dye was removed with a NAP-10 Sephadex size exclusion column (GE Healthcare) and by repeated centrifugal filtration against a 100 kDa MWCO membrane.
Modification with NHS PEG.
A solution of creatine kinase (100 μM) in 10 mM phosphate buffer, pH 7.5 was incubated with NHS-functionalized PEG (tBoc-PEG-succinimidyl carboxymethyl, MW = 5000, Laysan Bio., Inc) for 2 h at room temperature. The PEG was dissolved in ddH 2 O immediately prior to use. The reaction was analyzed by SDS-PAGE without any prior purification. Figure S1 . The effect of pH on the reactivity of the N-terminus with o-aminophenols was tested. Angiotensin I (100 μM) was reacted with 2-amino-p-cresol (100 μM) in the presence of K 3 Fe(CN) 6 (1 mM) in 10 mM phosphate buffer at a pH range of 5.5-8.5 (expected mass addition = +120). For clarity, the peaks for the potassium adducts are also labeled. Figure S3 . Several peptides were screened for their ability to react with o-aminophenols in the presence of ferricyanide. Reactions were run with approximately 0.1 mM peptide, 0.1 mM o-aminophenol and 1 mM ferricyanide in phosphate buffer, pH 7.5. All of the peptides showed some degree of modification (expected mass addition = +120), with the exception of the hypertrehalosemic neuropeptide. For clarity, the peaks for the potassium adducts are also labeled. S.14 Optimization of reactivity on peptide substrates Figure S4 . Peptides were screened in several different buffers at pH 7.5 to determine the buffer salt compatibility of the reaction. Most buffers showed no effect on the reaction; however a few buffers inhibited the reaction. The buffers that diminished reactivity generally contained a morpholino or piperazine moiety. Reactions were run with approximately 0.1 mM peptide, 0.1 mM o-aminophenol, and 1 mM ferricyanide at pH 7.5 for 30 minutes.
S.11 Aminophenol reactivity with native amino acids on peptides
GPS peptide
angiotensin I DRVYIHPFHL
conditions : 100 μM peptide, 100 μM aminophenol, 1 mM ferricyanide, 10 mM phosphate buffer pH 7. Figure S5 . The time course of the reaction was assayed using angiotensin I as a substrate. The reactions were co-crystallized with matrix on a MALDI plate at the indicated time (expected mass addition = +120). For clarity, the peaks for the potassium adducts are also labeled. S13 Figure S6 . The effect of pH on the reactivity of the N-terminus with o-catechols was tested. Angiotensin I (100 μM) was reacted with 4-methylcatechol (100 μM) in the presence of K 3 Fe(CN) 6 (1 mM) in 10 mM phosphate buffer at a pH range of 5.5-8.5 (expected mass addition = +120). For clarity, the peaks for the potassium adducts are also labeled. . The effect of pH on the reactivity of the N-terminus with o-aminophenols was tested. Angiotensin I (100 μM) was reacted with 2-amino-p-cresol (100 μM) in the presence of NaIO 4 (1 mM) in 10 mM phosphate buffer at a pH range of 5.5-8.5 (expected mass addition = +120). For clarity, the peaks for the potassium adducts are also labeled. Figure S8 . Representative mass spectra of XADSWAG peptides after reaction with 2 equiv of 2-amino-p-cresol in the presence of 5 mM ferricyanide.
S.15 MS of N-terminal variant peptides (XADSWAG) after modification
S16
S.16 Characterization of small molecule products Figure S9 . HMBC spectrum of S2 in CD 3 CN. 
